Abstract 15271: Oral Anticoagulation versus Antiplatelet Therapy After Percutaneous Left Atrial Appendage Occlusion: A Real-World Comparative Analysis
Abstract
Introduction: Optimal antithrombotic therapy after percutaneous left atrial appendage occlusion (LAAO) remains uncertain. Although oral anticoagulants (OACs) and antiplatelet therapy (APT) are commonly used, comparative real-world data on long-term outcomes are limited. We aimed to compare the long-term effectiveness and safety of OACs versus APT-based antithrombotic strategies following percutaneous LAAO. Hypothesis: We hypothesized that post-percutaneous LAAO management with OACs provides comparable thromboembolic protection but differs in cumulative bleeding complications compared with APT over a 2-year follow-up. Methods: Using the TriNetX US Collaborative Network, adults with nonvalvular atrial fibrillation who underwent percutaneous LAAO were identified. Patients initiated on OACs (rivaroxaban, apixaban, dabigatran, warfarin, or edoxaban) (Cohort 1) versus APT (Cohort 2) within one month post-procedure were compared. Patients with mechanical valves, venous thromboembolism, or thrombophilia were excluded. A 1:1 propensity score matching was performed. . The primary efficacy endpoint was a composite of cerebral infarction and arterial embolism/thrombosis. The primary safety endpoint was a composite of intracranial hemorrhage and gastrointestinal bleeding. Outcomes were assessed at 2 years follow-up period using Kaplan-Meier survival analysis. Results: Following propensity score matching, 6,980 patients were analyzed (n=3,490 per cohort). At 2 years, no significant difference was observed in the efficacy composite between OAC and APT (HR 1.21; 95% CI 0.89-1.63; p=0.94). For the safety composite, OAC demonstrated significantly lower cumulative major bleeding risk compared with APT (HR 0.73; 95% CI 0.57-0.92; p=0.008). Kaplan-Meier curves are shown in Figure 1. Conclusion: In this large propensity-matched real-world analysis, post-percutaneous LAAO OAC achieved comparable thromboembolic protection, but significantly lower long-term bleeding risk compared with APT from 6 months onward. These findings challenge conventional assumptions regarding OAC-related haemorrhage in post-percutaneous LAAO patients and suggest OAC may offer superior net clinical benefit over prolonged antiplatelet strategies.